$159.14
10.09% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$159.14
-16.97 9.64% 1M
+85.02 114.71% 6M
+80.21 101.62% YTD
+102.23 179.63% 1Y
+127.93 409.90% 3Y
+135.45 571.76% 5Y
+143.14 894.63% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+14.58 10.09%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Market capitalization $4.82b
Enterprise Value $4.98b
P/E (TTM) P/E ratio 4,049.30
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.87
P/S ratio (TTM) P/S ratio 13.44
P/B ratio (TTM) P/B ratio 25.36
Revenue growth (TTM) Revenue growth 137.47%
Revenue (TTM) Revenue $358.76m
EBIT (operating result TTM) EBIT $26.41m
Free Cash Flow (TTM) Free Cash Flow $-193.76m
Cash position $362.75m
EPS (TTM) EPS $0.04
P/E forward 118.98
P/S forward 10.85
EV/Sales forward 11.20
Short interest 21.47%
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
90%
Hold
10%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
359 359
137% 137%
100%
- Direct Costs 141 141
202% 202%
39%
218 218
109% 109%
61%
- Selling and Administrative Expenses 129 129
48% 48%
36%
- Research and Development Expense 47 47
76% 76%
13%
41 41
524% 524%
11%
- Depreciation and Amortization 15 15
159% 159%
4%
EBIT (Operating Income) EBIT 26 26
272% 272%
7%
Net Profit 3 3
117% 117%
1%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Neutral
PRNewsWire
about 4 hours ago
ANDOVER, Mass. , Sept. 27, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on September 24, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 336 shares of its common stock and an ...
Neutral
PRNewsWire
one day ago
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE: SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the open...
Positive
Seeking Alpha
18 days ago
TransMedics is revolutionizing organ transportation with its FDA-approved Organ Care System, improving organ functionality during transport. Significant investments in logistics, including owning aircraft, enhancing its moat, reducing graft dysfunction by 50% and improving donation effectiveness. The company has a strong competitive edge, evident in its 100%+ YoY sales growth and 10-12% net mar...
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 584
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today